Envoy Medical, Inc.
No SEC Form 4 filings for $COCH in the last 30 days.
See all $COCH insider activity →Envoy Medical (NASDAQ: COCH) will release Q3 2026 financial results on November 5, 2026, followed by a conference call. The company specializes in hearing health and neuroprosthetics, offering implanted hearing solutions. A replay will be available until November 19, 2026.
Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Envoy Medical Announces Reverse Stock Split White Bear Lake, Minnesota – October 22, 2026 – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announ
Envoy Medical (COCH) announced a 1-for-10 reverse stock split, effective October 26, 2026, to meet Nasdaq's $1.00 minimum price requirement. Shares fell 8% premarket.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning COCH (Envoy Medical, Inc.). Coverage has been balanced: 1 bullish, 4 neutral, and 1 bearish.
Recent COCH coverage spans corporate actions, earnings and financial news.
Upcoming earnings announcement may cause modest price movement.
The split will raise the share price ~10× and may attract institutional investors, but no fundamental change to the business.
The reverse split is intended to lift the share price above Nasdaq's $1 minimum, but such splits often trigger short‑term selling pressure.
The milestone confirms trial progress and keeps the company on track for a 12‑month data readout and FDA decision in 2027.
The approved reverse split may cause short‑term price volatility as the market adjusts the share count.
AlphAI scores every news story that mentions COCH with an AI model for sentiment and relevance, and aggregates insider trades from Envoy Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Envoy Medical (NASDAQ: COCH) will release Q3 2026 financial results on November 5, 2026, followed by a conference call. The company specializes in hearing health and neuroprosthetics, offering implanted hearing solutions. A replay will be available until November 19, 2026.
1 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Envoy Medical Announces Reverse Stock Split White Bear Lake, Minnesota – October 22, 2026 – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announ
2 min readEnvoy Medical (COCH) announced a 1-for-10 reverse stock split, effective October 26, 2026, to meet Nasdaq's $1.00 minimum price requirement. Shares fell 8% premarket.
1 min readEnvoy Medical (NASDAQ: COCH) announced it has reached the six-month milestone in its pivotal clinical trial for the Acclaim® cochlear implant, the halfway point in data collection. The company expects to complete 12-month visits by early Q2 2027 and submit the final PMA module by the end of Q2 2027. Envoy Medical claims its device is the first of its kind in a U.S. pivotal trial and highlights its differentiated design.
2 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 12, 2026, Envoy Medical, Inc., a Delaware corporation (the “ Company ”), held a Special Meeting of Stockholders (the “ Special Meeting ”). At the Special Meeting, the Company’s stockholders (the “ Stockhold
1 min readEnvoy Medical (COCH) submitted the second of four planned PMA modules to the FDA for its Acclaim cochlear implant, with the final clinical module targeted for Q2 2027. This follows the first module submission in June 2026, according to the company.
1 min readEnvoy Medical (COCH) settled litigation with Atlas Merchant Capital, dismissing all claims without payment. The case involved alleged redemption rights from their 2023 business combination. The agreement ends further legal proceedings.
1 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 6, 2026, Envoy Medical, Inc., a Delaware corporation (the “Company”), entered into a Dismissal Agreement (the “Dismissal Agreement”) regarding litigation in the Delaware Court of Chancery (the “Litigation”) with Atlas Merchant Capital SPAC Fund
1 min readLake Street initiated coverage on Envoy Medical (COCH) with a buy rating and $2.50 price target, citing potential upside of 270%. The company's Acclaim cochlear implant is in development, with pivotal trial data meeting expectations. Envoy reported Q2 2026 revenue of $51,000 and a net loss of $7.3 million. Other analysts maintain buy ratings with varying price targets.
2 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On August 24, 2026, Envoy Medical, Inc. (the “Company”) appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. M
1 min read
